Literature DB >> 28001091

Treatment options for recurrent high-grade gliomas.

Harjus S Birk1, Seunggu J Han1, Nicholas A Butowski1.   

Abstract

High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.

Entities:  

Keywords:  glioblastoma; high-grade gliomas; overall survival; progression-free survival; recurrence treatment

Mesh:

Substances:

Year:  2016        PMID: 28001091      PMCID: PMC6027924          DOI: 10.2217/cns-2016-0013

Source DB:  PubMed          Journal:  CNS Oncol        ISSN: 2045-0907


  48 in total

1.  Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy.

Authors:  Ellen S Mandl; C M F Dirven; D R Buis; T J Postma; W P Vandertop
Journal:  Surg Neurol       Date:  2008-02-08

2.  Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.

Authors:  M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

3.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

Authors:  Orin Bloch; Courtney A Crane; Yelena Fuks; Rajwant Kaur; Manish K Aghi; Mitchel S Berger; Nicholas A Butowski; Susan M Chang; Jennifer L Clarke; Michael W McDermott; Michael D Prados; Andrew E Sloan; Jeffrey N Bruce; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2013-12-12       Impact factor: 12.300

4.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

5.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  Michael D Prados; Kathleen Lamborn; W K A Yung; Kurt Jaeckle; H Ian Robins; Minesh Mehta; Howard A Fine; Patrick Y Wen; Timothy Cloughesy; Susan Chang; M Kelly Nicholas; David Schiff; Harry Greenberg; Larry Junck; Karen Fink; Ken Hess; John Kuhn
Journal:  Neuro Oncol       Date:  2006-03-13       Impact factor: 12.300

6.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

9.  Rechallenge with temozolomide in patients with recurrent gliomas.

Authors:  Antje Wick; Christina Pascher; Wolfgang Wick; Tanja Jauch; Michael Weller; Ulrich Bogdahn; Peter Hau
Journal:  J Neurol       Date:  2009-02-25       Impact factor: 4.849

10.  Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Authors:  James R Perry; Philippe Rizek; Rosemary Cashman; Meredith Morrison; Tara Morrison
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

View more
  17 in total

1.  Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO).

Authors:  Pierina Navarria; Giuseppe Minniti; Elena Clerici; Stefano Tomatis; Valentina Pinzi; Patrizia Ciammella; Marco Galaverni; Dante Amelio; Daniele Scartoni; Silvia Scoccianti; Marco Krengli; Laura Masini; Lorena Draghini; Ernesto Maranzano; Valentina Borzillo; Paolo Muto; Fabio Ferrarese; Laura Fariselli; Lorenzo Livi; Francesco Pasqualetti; Alba Fiorentino; Filippo Alongi; Michela Buglione di Monale; Stefano Magrini; Marta Scorsetti
Journal:  J Neurooncol       Date:  2018-12-04       Impact factor: 4.130

2.  Homeobox B8 Targets Sterile Alpha Motif Domain-Containing Protein 9 and Drives Glioma Progression.

Authors:  Wenping Ma; Hongze Jin; Wenjie Liu; Xiaojuan Li; Xingang Zhou; Xinwu Guo; Runfa Tian; Qi Cui; Junjie Luo; Yueying Jiao; Youtao Yu; Haifeng Yang; Hongshan Zhao
Journal:  Neurosci Bull       Date:  2019-10-23       Impact factor: 5.203

3.  Tudor-staphylococcal nuclease regulates the expression and biological function of alkylglycerone phosphate synthase via nuclear factor-κB and microRNA-127 in human glioma U87MG cells.

Authors:  Yongqiang Zhang; Jun Jia; Ying Li; Yan-Ge Chen; Huan Huang; Yang Qiao; Yu Zhu
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

4.  Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

Authors:  So Young Ji; Jongjin Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong Hwy Kim; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Yongdai Kim; Chul-Kee Park
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

5.  Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.

Authors:  Francesco Pasqualetti; Nicola Montemurro; Isacco Desideri; Mauro Loi; Noemi Giannini; Giovanni Gadducci; Giulia Malfatti; Martina Cantarella; Alessandra Gonnelli; Sabrina Montrone; Luca Visani; Cristian Scatena; Antonio Giuseppe Naccarato; Paolo Perrini; Carlo Gambacciani; Orazio Santonocito; Riccardo Morganti; Fabiola Paiar
Journal:  Acta Neurol Belg       Date:  2021-08-16       Impact factor: 2.396

6.  Activation of dopamine receptor D1 inhibits glioblastoma tumorigenicity by regulating autophagic activity.

Authors:  Kang Yang; Minghai Wei; Zhaofei Yang; Zhenfa Fu; Ruixue Xu; Cheng Cheng; Xi Chen; Sheng Chen; Eric Dammer; Weidong Le
Journal:  Cell Oncol (Dordr)       Date:  2020-08-06       Impact factor: 6.730

7.  MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.

Authors:  H J Choi; S H Choi; S-H You; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn; C-K Park; S-H Park
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

8.  High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?

Authors:  T Gupta; M Maitre; P Maitre; J S Goda; R Krishnatry; A Chatterjee; A Moiyadi; P Shetty; S Epari; A Sahay; V Patil; R Jalali
Journal:  Clin Transl Oncol       Date:  2021-02-02       Impact factor: 3.405

9.  Anatomic and Molecular MR Image Synthesis Using Confidence Guided CNNs.

Authors:  Pengfei Guo; Puyang Wang; Rajeev Yasarla; Jinyuan Zhou; Vishal M Patel; Shanshan Jiang
Journal:  IEEE Trans Med Imaging       Date:  2021-09-30       Impact factor: 11.037

10.  Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.

Authors:  Anna Gieryng; Dominika Pszczolkowska; Katarzyna Bocian; Michal Dabrowski; Wenson David Rajan; Michal Kloss; Jakub Mieczkowski; Bozena Kaminska
Journal:  Sci Rep       Date:  2017-12-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.